<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg"/></p>
<p>設施擴建被認為能夠支持 Alnylam 開發管線未來藥物的推出。圖片來源：Bo Shen / Shutterstock.com。</p>
<p>Alnylam 製藥公司計劃在美國馬薩諸塞州諾頓市投資 2.5 億美元，以滿足全球對 RNA 干擾（RNAi）治療藥物日益增長的需求。</p>
<p>這將成為首個完全專用的小干擾 RNA（siRNA）酶連接製造設施。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: ALLO-501</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: ALLO-501A</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>設施擴建旨在提高產能，降低生產成本，並支持公司開發管線未來藥物的推出。</p>
<p>作為此計劃的一部分，公司下一代可擴展的酶連接製造平台 siRELIS 已被納入美國食品藥品監督管理局的前沿技術計劃。</p>
<p>該計劃預計將促進與全球衞生當局就基於寡核苷酸藥物的製造方法進行討論。</p>
<p>這一接受是在對 zilebesiran 進行小規模生產後，該藥物正在研究降低高血壓患者重大不良心血管事件的風險，以及 nucresiran，正在開發用於轉甲狀腺素介導的澱粉樣變性（ATTR）。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<p>siRELIS 平台使 RNAi 治療藥物的製造所需的材料和工廠資源減少，支持可持續的大規模生產。</p>
<p>公司 20 萬平方英尺的諾頓設施擴建允許在當地生產臨牀和商業供應的 siRNA 寡核苷酸藥物原料，服務全球患者。</p>
<p>該設施自 2021 年開始運營，已為 Alnylam 的臨牀管線增長做出貢獻，並支持針對多種組織類型的早期項目，包括中樞神經系統（CNS）、肝臟、肌肉和脂肪組織。</p>
<p>該地點的建設目前正在進行中，預計新設施將在 2027 年底前全面投入運營。</p>
<p>Alnylam 製藥公司首席執行官 Yvonne Greenstreet 表示：“在我們 RNAi 治療藥物管線擴展的關鍵時刻，Alnylam 正在加速 siRNA 製造的發展，並改變單一設施的可能性。</p>
<p>“這一進展將是我們管線擴展的關鍵推動力，包括潛在治療高血壓、2 型糖尿病和肥胖等疾病。”</p>
<p>2025 年 6 月，歐洲委員會批准了 Alnylam 的 Amvuttra（vutrisiran），用於治療成人的野生型或遺傳性轉甲狀腺素澱粉樣變性伴心肌病。</p>
<h2>製藥技術卓越獎 - 提名已關閉</h2>
<p>提名現已關閉，感謝所有參與的組織——你們的響應非常出色，展示了卓越的創新、領導力和影響力。</p>
<p><strong>行動中的卓越</strong></p>
<p>Upperton Pharma Solutions 因在 綜合製造 方面的業務擴展獲得 2025 年製藥技術卓越獎，正在迅速擴展其在英國的 GMP 和無菌製造能力。瞭解 Upperton 的綜合 CDMO 模型如何幫助製藥公司從早期開發轉向臨牀和小眾商業供應，減少交接和加快時間表。</p>
<p>發現影響</p>

阿里拉姆制藥

<p>阿里拉姆製藥計劃在其諾頓製造設施投資 2.5 億美元，以增強其 siRELIS 平台用於 RNA 干擾治療。美國食品藥品監督管理局的前沿技術計劃已接受該平台，促進了關於寡核苷酸藥物製造的討論。此次擴展支持可持續的大規模生產和 siRNA 藥物物質的本地供應。該設施自 2021 年投入運營，助力阿里拉姆的臨牀管線增長，針對多種組織。預計到 2027 年底將達到全面運營能力，從而能夠治療高血壓、2 型糖尿病和肥胖症</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/Alnylam18Dec-shutterstock_2714580617-430x241.jpg"/></p>
<p>The facility expansion is said to enable support for future medicine launches from Alnylam’s development pipeline. Credit: Bo Shen / Shutterstock.com.</p>
<div class="lb-trans"><p>設施擴建被認為能夠支持 Alnylam 開發管線未來藥物的推出。圖片來源：Bo Shen / Shutterstock.com。</p>
</div><p>Alnylam Pharmaceuticals is set to invest $250m in the expansion of its facility in Norton, Massachusetts, US, to meet the growing global demand for RNA interference (RNAi) therapeutics.</p>
<div class="lb-trans"><p>Alnylam 製藥公司計劃在美國馬薩諸塞州諾頓市投資 2.5 億美元，以滿足全球對 RNA 干擾（RNAi）治療藥物日益增長的需求。</p>
</div><p>This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility.</p>
<div class="lb-trans"><p>這將成為首個完全專用的小干擾 RNA（siRNA）酶連接製造設施。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: ALLO-501</h4>
<div class="lb-trans"><h4>NPVM: ALLO-501</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: ALLO-501A</h4>
<div class="lb-trans"><h4>NPVM: ALLO-501A</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The facility expansion is intended to increase capacity, lower production expenses, and enable support for future medicine launches from the company’s development pipeline.</p>
<div class="lb-trans"><p>設施擴建旨在提高產能，降低生產成本，並支持公司開發管線未來藥物的推出。</p>
</div><p>As part of this, the company’s next-generation, scalable enzymatic ligation manufacturing platform, known as siRELIS, has been accepted into the US Food and Drug Administration’s Emerging Technology Program.</p>
<div class="lb-trans"><p>作為此計劃的一部分，公司下一代可擴展的酶連接製造平台 siRELIS 已被納入美國食品藥品監督管理局的前沿技術計劃。</p>
</div><p>The programme is expected to facilitate discussions with global health authorities regarding manufacturing approaches for oligonucleotide-based medicines.</p>
<div class="lb-trans"><p>該計劃預計將促進與全球衞生當局就基於寡核苷酸藥物的製造方法進行討論。</p>
</div><p>This acceptance comes after pilot-scale production of zilebesiran, which is under investigation for decreasing the risk of major adverse cardiovascular events in hypertension patients, and nucresiran, being developed for transthyretin-mediated amyloidosis (ATTR).</p>
<div class="lb-trans"><p>這一接受是在對 zilebesiran 進行小規模生產後，該藥物正在研究降低高血壓患者重大不良心血管事件的風險，以及 nucresiran，正在開發用於轉甲狀腺素介導的澱粉樣變性（ATTR）。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>The siRELIS platform enables RNAi therapeutic manufacturing with reduced material and plant resource requirements, supporting sustainable, large-scale production.</p>
<div class="lb-trans"><p>siRELIS 平台使 RNAi 治療藥物的製造所需的材料和工廠資源減少，支持可持續的大規模生產。</p>
</div><p>The company’s 200,000ft² Norton facility expansion allows for local production of both clinical and commercial supplies of siRNA oligonucleotide drug substance for patients worldwide.</p>
<div class="lb-trans"><p>公司 20 萬平方英尺的諾頓設施擴建允許在當地生產臨牀和商業供應的 siRNA 寡核苷酸藥物原料，服務全球患者。</p>
</div><p>Operational since 2021, the facility has contributed to the growth of Alnylam’s clinical pipeline and supports early-stage programmes targeting various tissue types, including the central nervous system (CNS), liver, muscle, and adipose tissue.</p>
<div class="lb-trans"><p>該設施自 2021 年開始運營，已為 Alnylam 的臨牀管線增長做出貢獻，並支持針對多種組織類型的早期項目，包括中樞神經系統（CNS）、肝臟、肌肉和脂肪組織。</p>
</div><p>Construction at the site is currently underway, with the new offerings anticipated to be completely operational by late 2027.</p>
<div class="lb-trans"><p>該地點的建設目前正在進行中，預計新設施將在 2027 年底前全面投入運營。</p>
</div><p>Alnylam Pharmaceuticals CEO Yvonne Greenstreet said: “At this pivotal time with our expanding pipeline of RNAi therapeutics, Alnylam is accelerating development of siRNA manufacturing and changing what’s possible in a single facility.</p>
<div class="lb-trans"><p>Alnylam 製藥公司首席執行官 Yvonne Greenstreet 表示：“在我們 RNAi 治療藥物管線擴展的關鍵時刻，Alnylam 正在加速 siRNA 製造的發展，並改變單一設施的可能性。</p>
</div><p>“This advance will be a critical enabler in the scaling of our pipeline to include potential treatments for diseases such as hypertension, type 2 diabetes, and obesity.”</p>
<div class="lb-trans"><p>“這一進展將是我們管線擴展的關鍵推動力，包括潛在治療高血壓、2 型糖尿病和肥胖等疾病。”</p>
</div><p>In June 2025, the European Commission approved Alnylam’s Amvuttra (vutrisiran) for the treatment of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.</p>
<div class="lb-trans"><p>2025 年 6 月，歐洲委員會批准了 Alnylam 的 Amvuttra（vutrisiran），用於治療成人的野生型或遺傳性轉甲狀腺素澱粉樣變性伴心肌病。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 提名已關閉</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名現已關閉，感謝所有參與的組織——你們的響應非常出色，展示了卓越的創新、領導力和影響力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行動中的卓越</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>Upperton Pharma Solutions 因在 綜合製造 方面的業務擴展獲得 2025 年製藥技術卓越獎，正在迅速擴展其在英國的 GMP 和無菌製造能力。瞭解 Upperton 的綜合 CDMO 模型如何幫助製藥公司從早期開發轉向臨牀和小眾商業供應，減少交接和加快時間表。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>發現影響</p>
</div>

阿里拉姆製藥計劃在美國諾頓的製造設施投資 2.5 億美元